Genus plc (LSE:GNS) has reported solid full-year results for FY25, with overall group performance meeting expectations. The company saw double-digit growth in adjusted operating profit for its PIC division, supported by a £3.7 million milestone payment tied to the U.S. FDA’s approval of its gene-edited PRRS Resistant Pig. Meanwhile, its ABS division outperformed expectations in the second half, benefiting from the ongoing Value Acceleration Programme, which delivered £8.5 million in efficiencies.
Genus now anticipates its adjusted profit before tax will reach at least £72 million, reflecting improved cash flow and a reduction in leverage. The FDA’s approval represents a landmark achievement in animal biotechnology, strengthening Genus’s position as a global leader in animal genetics and opening the door to future growth opportunities.
Despite these positive developments, the company’s financial outlook remains balanced. While strategic milestones support a favorable long-term narrative, current valuation concerns and mixed technical signals may limit near-term gains.
About Genus plc
Genus plc is a global pioneer in animal genetics, leveraging biotechnology to improve livestock breeding and productivity. The company supplies high-performance genetics to the dairy, beef, and pork industries, primarily through semen, embryos, and breeding stock. It operates under the brands ‘ABS’ (for cattle) and ‘PIC’ (for pigs), with a global footprint spanning more than 25 countries. Headquartered in Basingstoke, UK, Genus also runs advanced research facilities in Madison, Wisconsin, USA.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply